All In Biotech

Drug Trial Radar · NCT03972657

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

345

Planned (sponsor's estimate)

Start

Aug 12, 2019

Primary completion

Nov 15, 2027

Study completion Nov 15, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors. This study is looking at several other research questions, including: 1. Side effects that may be experienced by taking REGN5678 alone or in combination with cemiplimab 2. How REGN5678 alone or in combination with cemiplimab works in the body 3. How much REGN5678 and/or cemiplimab are present in the blood 4. To see if REGN5678 alone or in combination with cemiplimab works to reduce the size of the tumor by helping the immune system destroy the tumor

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

  • REGN5678Drug

    Administered as per the protocol

  • CemiplimabDrug

    Administered as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to 5 years
  2. Incidence and severity of Adverse Event of Special Interests (AESIs)Time frame: Through study completion, up to 5 years
  3. Incidence and severity of Serious Adverse Events (SAEs)Time frame: Through study completion, up to 5 years
  4. Number of participants with Grade ≥3 laboratory abnormalitiesTime frame: Through study completion, up to 5 years
  5. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: First dose through day 42 of last participant in each dose level
  6. Concentration of REGN5678 in serum over timeTime frame: Through study completion, up to 5 years
  7. Concentration of REGN5678 in combination with cemiplimab in serum over timeTime frame: Through study completion, up to 5 years
  8. Composite Response Rate (CRR) of 50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic response of complete (CR) or partial response (PR)Time frame: Through study completion, up to 5 years
  9. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaTime frame: Through study completion, up to 5 years

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • University of Arizona

    Tucson, Arizona · Recruiting

  • John Wayne Cancer Institute (JWCI)

    Santa Monica, California · Recruiting

  • Sarah Cannon Research Institute (SCRI)

    Denver, Colorado · Recruiting

  • Yale University Hospital

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center - McKinley Drive

    Tampa, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University - The Trustees of Columbia University in the City of New York

    New York, New York · Recruiting

  • Montefiore Medical Center

    New York, New York · Recruiting

  • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester

    Rochester, New York · Recruiting

  • James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Withdrawn

  • Oregon Health & Science University (3485 S. Bond)

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Lifespan Cancer Institute

    Providence, Rhode Island · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Emily Couric Clinical Cancer Center

    Charlottesville, Virginia · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • Yonsei University - Severance Hospital - Colorectal Cancer Clinic

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea - St. Vincent's Hospital - Lung Cancer Center

    Suwon, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.